ES2255181T3 - Antigeno inmunoprotector contra la gripe y su uso en vacunacion. - Google Patents

Antigeno inmunoprotector contra la gripe y su uso en vacunacion.

Info

Publication number
ES2255181T3
ES2255181T3 ES98946321T ES98946321T ES2255181T3 ES 2255181 T3 ES2255181 T3 ES 2255181T3 ES 98946321 T ES98946321 T ES 98946321T ES 98946321 T ES98946321 T ES 98946321T ES 2255181 T3 ES2255181 T3 ES 2255181T3
Authority
ES
Spain
Prior art keywords
baselineskip
antigen
protein
flu
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98946321T
Other languages
English (en)
Spanish (es)
Inventor
Sabine Neirynck
Willy Min Jou
Walter Fiers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie
Original Assignee
Vlaams Instituut voor Biotechnologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2255181(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vlaams Instituut voor Biotechnologie filed Critical Vlaams Instituut voor Biotechnologie
Application granted granted Critical
Publication of ES2255181T3 publication Critical patent/ES2255181T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES98946321T 1997-08-05 1998-08-05 Antigeno inmunoprotector contra la gripe y su uso en vacunacion. Expired - Lifetime ES2255181T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202434 1997-08-05
EP97202434 1997-08-05

Publications (1)

Publication Number Publication Date
ES2255181T3 true ES2255181T3 (es) 2006-06-16

Family

ID=8228624

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98946321T Expired - Lifetime ES2255181T3 (es) 1997-08-05 1998-08-05 Antigeno inmunoprotector contra la gripe y su uso en vacunacion.

Country Status (10)

Country Link
US (1) US7732130B2 (cg-RX-API-DMAC7.html)
EP (1) EP0996717B1 (cg-RX-API-DMAC7.html)
JP (2) JP5132851B2 (cg-RX-API-DMAC7.html)
AT (1) ATE312172T1 (cg-RX-API-DMAC7.html)
AU (1) AU745951B2 (cg-RX-API-DMAC7.html)
CA (1) CA2297786C (cg-RX-API-DMAC7.html)
DE (1) DE69832706T2 (cg-RX-API-DMAC7.html)
DK (1) DK0996717T3 (cg-RX-API-DMAC7.html)
ES (1) ES2255181T3 (cg-RX-API-DMAC7.html)
WO (1) WO1999007839A2 (cg-RX-API-DMAC7.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0996717B1 (en) 1997-08-05 2005-12-07 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoprotective influenza antigen and its use in vaccination
US7731972B1 (en) 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
AU5533601A (en) * 2000-04-14 2001-10-30 Wisconsin Alumni Res Found Viruses comprising mutation ion channel protein
WO2001083528A2 (en) * 2000-05-01 2001-11-08 Powderject Vaccines, Inc. Nucleic acid immunization
EP1278542A2 (en) 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
GB0025229D0 (en) * 2000-10-14 2000-11-29 Adprotech Ltd Veterinary immunisation vectors
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
GB0204154D0 (en) * 2002-02-22 2002-04-10 Adprotech Ltd Cat immunisation vectors
US20030219442A1 (en) * 2002-03-13 2003-11-27 Toshifumi Mikayama Human monoclonal antibodies to influenza M2 protein and methods of making and using same
AU2003246690B2 (en) 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
BR0312792A (pt) 2002-07-19 2005-05-03 Cytos Biotechnology Ag Composições de vacinas contendo séries antigênicas de amilóide beta1-6
JP2007525175A (ja) * 2003-04-23 2007-09-06 ウィスコンシン アルムニ リサーチ ファウンデイション 突然変異した膜タンパク質をその機能性の一部ウイルス
ES2317043T3 (es) * 2003-06-23 2009-04-16 Baxter International Inc. Proteinas portadoras para vacunas.
CN101103103A (zh) 2004-11-19 2008-01-09 威斯康星旧生研究基金会 具有串联转录单位的重组流感病毒载体
EP1819732A2 (en) 2004-12-06 2007-08-22 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
AU2006311752A1 (en) * 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center CD40 ligand fusion protein vaccine
DK1968632T3 (da) 2005-12-06 2012-07-16 Yeda Res & Dev Forbedret influenzavaccine
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
JP2009543554A (ja) 2006-07-14 2009-12-10 サノフィ パスツール バイオロジクス カンパニー ベクターウイルスタンパク質への外来免疫決定基の直接トランスポゾン媒介挿入による組換え型ウイルスワクチンの構築
EP2069483A4 (en) 2006-09-29 2010-10-27 Sanofi Pasteur Biologics Co RECOMBINANT RHINOVIRUS VECTORS
US20100111996A1 (en) * 2006-11-15 2010-05-06 Denis Leclerc Papaya Mosaic Virus-Based Vaccines for Influenza
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
WO2009016639A2 (en) 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
US9592285B2 (en) * 2007-11-12 2017-03-14 The Trustees Of The University Of Pennsylvania Vaccines against multiple subtypes of influenza virus
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
WO2010012069A1 (en) * 2008-07-30 2010-02-04 Folio Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
EP2168987A1 (en) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
EP2459716B1 (en) * 2009-07-31 2016-08-17 Paxvax, Inc. Adenoviral-based vectors
US8883165B2 (en) 2009-08-28 2014-11-11 The Chemo-Sero-Therapeutic Research Institute Modified peptide vaccine derived from influenza M2
WO2011046925A1 (en) * 2009-10-12 2011-04-21 Technovax, Inc. Respiratory syncytial virus (rsv) virus-like particles (vlps)
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
WO2011054995A2 (es) 2009-11-06 2011-05-12 Chimera Pharma, S. L. U. VACUNAS PROFILACTICAS DE GRIPE A PARTIR DE CAPSIDAS VIRALES DE BIRNAVIRUS CONTENIENDO EL ANTIGENO M2e DEL VIRUS DE LA GRIPE
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Mdck、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
EP3103474A1 (en) * 2015-06-12 2016-12-14 Institut Pasteur Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたb型インフルエンザウイルス複製
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたnaを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919044A (en) * 1973-03-28 1975-11-11 Armour Pharma Processes for concentrating and purifying viruses and viral antigens
NZ219516A (en) * 1987-02-10 1991-02-26 Wellcome Found Fusion proteins of hbcag (hepatitis b virus core antigen)
WO1992022575A1 (en) * 1991-06-19 1992-12-23 Sri International M-protein peptides of influenza virus as antiviral agents
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
ES2180576T3 (es) * 1993-04-27 2003-02-16 United Biomedical Inc Construcciones peptidicas de lhrh inmunogenicas y estimuladores de inmunidad universales sinteticos para vacunas.
JPH09500540A (ja) * 1993-07-30 1997-01-21 メデヴァ ホールディングス ビー.ヴイ. ワクチン組成物
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
GB9424631D0 (en) * 1994-12-06 1995-01-25 Lynxvale Ltd Modulating the immune response
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
DE69735376T2 (de) 1996-11-26 2006-12-14 Stressgen Biotechnologies Corp., Victoria Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort
EP0996717B1 (en) 1997-08-05 2005-12-07 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoprotective influenza antigen and its use in vaccination
US6169175B1 (en) * 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US20020015951A1 (en) 2000-01-06 2002-02-07 Bader Joel S. Method of analyzing a nucleic acid

Also Published As

Publication number Publication date
US20060246092A1 (en) 2006-11-02
DK0996717T3 (da) 2006-04-10
JP5132851B2 (ja) 2013-01-30
US7732130B2 (en) 2010-06-08
JP2010059164A (ja) 2010-03-18
WO1999007839A2 (en) 1999-02-18
DE69832706D1 (de) 2006-01-12
EP0996717A2 (en) 2000-05-03
AU9341698A (en) 1999-03-01
DE69832706T2 (de) 2006-08-10
WO1999007839A3 (en) 1999-05-14
CA2297786A1 (en) 1999-02-18
CA2297786C (en) 2011-06-14
EP0996717B1 (en) 2005-12-07
AU745951B2 (en) 2002-04-11
ATE312172T1 (de) 2005-12-15
JP2001512748A (ja) 2001-08-28

Similar Documents

Publication Publication Date Title
EP0996717B1 (en) Immunoprotective influenza antigen and its use in vaccination
US6544785B1 (en) Helper-free rescue of recombinant negative strand RNA viruses
US7993652B2 (en) Immunoprotective influenza antigen and its use in vaccination
US8372963B2 (en) RSV F-protein and its use
EA018174B1 (ru) Вирус гриппа с нарушенной репликацией для экспрессии гетерологичных последовательностей
JP2002524077A (ja) 抗原キャリヤーとしての弱毒化サルモネラspi2突然変異体
EP0201416B1 (fr) Particules ayant les propriétés immunogènes de l'antigène HBs et portant un site antigénique étranger aux épitopes portés par l'antigène HBs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
JP2001510039A (ja) 診断および治療に有用な呼吸器多核体ウイルスエピトープならびにそれらを含んでなる抗体
JP2010083898A (ja) Clostridiumdifficileに対する、組換え毒素A/毒素Bワクチン
CN1838967B (zh) 稳定的免疫原性HBc嵌合体颗粒
KR100970178B1 (ko) 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를 포함하는 항비만 백신 조성물
ES2276785T3 (es) Aislamiento y caracterizacion del operon csa (pili cs4 de etec) y metodos para usar el mismo.
CN111607605B (zh) 一种多价表位和亚单位疫苗的构建方法
KR100880477B1 (ko) 외인성 내부 에피토프를 갖는 바이러스 입자
CN110229219B (zh) 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途
ES2199460T3 (es) Polipeptidos del virus de la hepatitis b.
AU7530100A (en) Use of an outer membrane protein a of an enterobacterium associated with a rsv immunogenic peptide for preparing vaccines for intranasal administration
JPH10509865A (ja) 細菌膜上で発現される呼吸器多核体ウイルスプロテインg
KR0170032B1 (ko) 복합백신용재조합독감바이러스
PL199190B1 (pl) Ciałka inkluzyjne jako antygeny do pokarmowej immunizacji zwierząt
JP2002541815A (ja) ウシアデノウイルス1型から誘導された組換えアデノウイルスおよび変異アデノウイルス
HRP20000702A2 (en) Viral particles with exogenous internal epitopes
KR19980014794A (ko) C형 간염 바이러스의 구조단백질 코아, E1 및 E2 외피당단백질 유전자를 함유하는 재조합 아데노바이러스(Ad/HCV/E3)